2.06
+0.26(+14.44%)
Currency In USD
| Previous Close | 1.8 |
| Open | 1.89 |
| Day High | 2.06 |
| Day Low | 1.8 |
| 52-Week High | 1,095 |
| 52-Week Low | 1.7 |
| Volume | 308,685 |
| Average Volume | 657,842 |
| Market Cap | 6.24M |
| PE | -0.02 |
| EPS | -118.56 |
| Moving Average 50 Days | 4.99 |
| Moving Average 200 Days | 27.12 |
| Change | 0.26 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $2.07 as of February 16, 2025 at a share price of $2.06. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $2.07 as of February 16, 2025 at a share price of $2.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics Holdings, Inc. Highlights Progress
GlobeNewswire Inc.
Feb 06, 2025 1:15 PM GMT
Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Compan
CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Feb 06, 2025 1:00 AM GMT
SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
GlobeNewswire Inc.
Jan 06, 2025 1:00 PM GMT
SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics